UNSPSC 51111733: Bleomycin

This classification denotes a bleomycin antibiotic with the molecular formula C55H84N17O21S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40S1VHN69B, more generally known as bleomycin. European Medicines Agency schedules bleomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00842MIG. The term BLEOMYCIN is an International Non-Proprietary Name or INN. Most nations schedule bleomycin under HS 29419000 and SITC 54139. As of Q4 2014, BLEOMYCIN remains the US FDA Preferred Term for this commodity.

Bleomycin bears US NLM identifiers UMLS ID C0005740 and NCI Concept Code C313. SMILES: CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O.

UNSPSC 51111733 Bleomycin, a Commodity code, does not reflect the actual procurement activity tagged under this designation in recent state and local solicitations. The code's nominal scope—a chemotherapy agent—bears no relation to the opportunities recently posted: Seminole County, Florida is bidding naloxone and drug deactivation systems for community health delivery; the City of Tampa is procuring medical and first aid supplies for fire rescue operations; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is contracting for generic multi-source pharmaceuticals and over-the-counter products; and the Texas Health and Human Services Commission has issued a Request for Information on direct-to-manufacturer prescription programs. None of these solicitations target bleomycin or chemotherapy agents. The code shows a significant mismatch between its nominal taxonomy and the work actually being bought under it in recent state and local procurement activity.

Geographic activity spans Florida, Texas, Minnesota, Oregon (through MMCAP), and the broader southwest and midwest regions, with state health and human services departments and county health boards as primary issuing bodies. Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2026), the City of Tampa's sealed-bid solicitation for medical and first aid supplies estimated at $700,000 with a March 13, 2026 response date and Small Local Business Enterprise set-aside eligibility, MMCAP's RFP for generic pharmaceuticals and OTC products (due March 26, 2026) serving multiple states, and the Texas HHS Commission's RFI on direct-to-manufacturer prescription capabilities (posted April 3, 2026). The code does not reflect coherent procurement activity in pharmaceutical specialization or chemotherapy supply chains and should be reconsidered for any firms targeting oncology-related state and local health contracting.